Medical Developments International’s product accepted for review in Canada

Company News

by Jessica Amir

Medical Developments International Limited (ASX:MVP) has announced the Canadian regulatory body, Health Canada, has accepted its Penthrox regulatory dossier for review.

The healthcare product company says accepting the single use inhaler device for review, triggers a milestone payment to be made to the company.

Medical Developments International is set to receive a quarter of a million Canadian dollars [CAD$0.25 million] from its partner, Purdue Pharma (Canada).

The company says it is a positive step towards globalising its product, Penthrox.

Shares in Medical Developments International Limited (ASX:MVP) are trading 0.93 per cent lower to $5.34.


 

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?